Pasithea Therapeutics Corp.(KTTA)

Biotechnology · Miami Beach, FL

$0.45-0.00 (-0.33%)

Delayed quote: Oct 6, 2026, 11:26 AM EDT

Pasithea Therapeutics (KTTA) EBITDA Yield: History & Chart | TGMCharts

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T15:33:35.513Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:33:35.513Z.

Quote observation: 2026-10-06T15:26:31.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -23,301,928
Quote market capitalization: 15,150,110
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 45,663,782,000

FMP input reference: b407bf9ab9426f7f8731c51b1e955f2cfcbe23f9f3e819a9868889fb687bb4da

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KTTA EBITDA Yield Metrics

EBITDA YIELD

N/A

KTTA Competitors' EBITDA Yield

KTTA

Pasithea Therapeutics Corp.

Current

Market Cap

$15.15M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KPTI

Karyopharm Therapeutics Inc.

vs KTTA

Market Cap

$15.10M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COCP

Cocrystal Pharma, Inc.

vs KTTA

Market Cap

$15.58M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OBX

Obsidian Therapeutics Inc.

vs KTTA

Market Cap

$14.53M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALLR

Allarity Therapeutics, Inc.

vs KTTA

Market Cap

$15.83M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSM

Pulsenmore Ltd. Ordinary Shares

vs KTTA

Market Cap

$14.37M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BCDA

BioCardia, Inc.

vs KTTA

Market Cap

$16.08M

EBITDA Yield

N/A

TTM Avg

7.50%

3Y Avg

7.48%

5Y Avg

7.48%

CTXR

Citius Pharmaceuticals, Inc.

vs KTTA

Market Cap

$14.15M

EBITDA Yield

N/A

TTM Avg

0.87%

3Y Avg

0.87%

5Y Avg

0.87%

HIND

Vyome Holdings, Inc.

vs KTTA

Market Cap

$13.97M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BNGO

Bionano Genomics, Inc.

vs KTTA

Market Cap

$16.81M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Pasithea Therapeutics Corp. (KTTA)	$15.15M	N/A	N/A	N/A	N/A
Karyopharm Therapeutics Inc. (KPTI)vs ›	$15.10M	N/A	N/A	N/A	N/A
Cocrystal Pharma, Inc. (COCP)vs ›	$15.58M	N/A	N/A	N/A	N/A
Obsidian Therapeutics Inc. (OBX)vs ›	$14.53M	N/A	N/A	N/A	N/A
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.83M	N/A	N/A	N/A	N/A
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.37M	N/A	N/A	N/A	N/A
BioCardia, Inc. (BCDA)vs ›	$16.08M	N/A	7.50%	7.48%	7.48%
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$14.15M	N/A	0.87%	0.87%	0.87%
Vyome Holdings, Inc. (HIND)vs ›	$13.97M	N/A	N/A	N/A	N/A
Bionano Genomics, Inc. (BNGO)vs ›	$16.81M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

KTTA EBITDA Yield Metrics

KTTA Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics